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Abstract 
Myeloid-derived suppressor cells are a heterogeneous group of immature myeloid cells with 
immunoregulatory function. When activated and expanded, these cells can suppress T cell functions via 
cell-to cell interactions as well as soluble mediators. Recent studies investigated the involvement of 
MDSC in autoimmune diseases. Some papers have described beneficial effect of MDSC during the course 
of autoimmune diseases, and suggest a potential role as a treatment option, while others failed to 
detect these effects. Their contributions to autoimmune diseases are not fully understood, and many 
questions and some controversies remain as to the expansion, activation, and inhibitory functions of 
MDSC. This review aims to summarize current knowledge of MDSC in autoimmune disorders.  
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Introduction. 
Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of bone marrow-
derived myeloid progenitors that fail to differentiate into mature myeloid cells. In steady state 
conditions, MDSC precursors reside primarily in the bone marrow (1). In a large variety of pathological 
conditions such as malignant tumors, infections, transplanted organs and inflammatory disorders 
including autoimmune diseases, MDSC populations expand and can be detected in the blood, peripheral 
lymphoid tissues, the spleen, cancerous tissues and inflammatory sites including different organs. After 
migrating from the bone marrow, MDSC inhibit other immune cells and normally prevent immune 
responses (2).  
 The frequency of MDSC can be closely associated with disease progression and clinical staging 
in some cancer patients and tumor bearing mice. However their dynamics, function and effect on the 
immune response in other conditions are less well-understood. In vitro generation and expansion of 
MDSC has become possible, and the therapeutic applications of these cells are also being explored: the 
manipulation of MDSC is being considered as a potential strategy as an effective immunotherapy for 
cancer (3).  
Contrary to cancer, only limited and sometimes contradictory information is available on these 
cells in autoimmune diseases; MDSC have been reported to affect autoimmunity in several ways. This 
review aims to present some current findings on MDSC in autoimmune conditions.  
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Phenotypic and functional characteristics of MDSC 
Classification of murine MDSC was initially was based on cell surface expression of CD11b and 
Gr-1. The CD11b
+
Gr-1
+
 subgroup are now further divided into two groups, exhibiting either a monocytic 
morphology or a granulocytic morphology. Granulocytic MDSC (g-MDSC) display a CD11b
+
Ly6C
low
 Ly6G
+
 
phenotype while monocytic MDSC (m-MDSC) are characterized as CD11b
+
Ly6C
high
Ly6G
- 
(4-7).  
In humans, MDSC are characterized by an “immature” phenotype on the basis of expression of 
CD33, and the absence/low levels of HLA-DR. MDSC also express the common myeloid marker CD11b, 
found on granulocytes, monocytes, and macrophages. CD14 and CD15 have been suggested as markers 
for m-MDSC and g-MDSC, respectively: human MDSC could be categorized as granulocytic (CD15
+
 or 
CD66b
+
 cells showing polymorphonuclear morphology), and monocytic (CD14
+
 cells showing 
mononuclear morphology) subsets. The two subsets are heterogeneous regarding nuclear morphology, 
and display differences in their suppressive capacity and functional mechanism depending on the actual 
disease (8-10) (Table 1). 
MDSC require different signals for their expansion, activation and migration. The factors are 
responsible for driving the expansion of MDSC, trigger signaling pathways that support the proliferation 
in the bone marrow, and block their differentiation into mature cells. These include cyclooxygenase-2, 
prostaglandins, interleukin 6 (IL-6), macrophage colony-stimulating factor (M-CSF), granulocyte-
macrophage colony-stimulating factor (GM-CSF), interferon gamma (IFN-γ) and transforming growth 
factor beta (TGF-β) (11-14). Tumor necrosis factor (TNF) signaling drives MDSC accumulation in the 
periphery by promoting MDSC survival and inhibiting apoptosis (15). Cancer models have established an 
important role of IL-6, IL-1β, prostaglandin E2, and the calcium binding proteins S100A8 and S100A9 for 
the accumulation of MDSC at sites of inflammation (16).  
MDSC suppress T cell functions via a number of different mechanisms involving both soluble 
mediators and cell-cell contact. G-MDSC usually inhibit T cell function through arginase-1 enzyme 
activity, while m-MDSC inhibit T cell functions via nitric oxide production. Activation by IFN-γ results in 
the upregulation of both arginase-1 and nitric oxide production. CD11b
+
Gr-1
+
 cells were also shown to 
inhibit CD8
+
 and CD4
+
 T cell activity via nitric oxide- and IL-10-dependent mechanisms. Reactive oxygen 
species (ROS) represent another suppressor mechanism, and peroxynitrite was identified as a mediator 
of suppression of T cell function by MDSC (17-19). MDSC also facilitate the suppressive functions of 
regulatory T cell (Treg). In a mouse model of autoimmune diabetes, MDSC induced the antigen-specific 
expansion of Treg, and prevented the development of the disease (20). When MDSC mixed with islet 
allografts were transplanted into diabetic mice, allografts were protected without immunosuppression. 
This was associated with attenuation of CD8 T cells as well as marked expansion Treg in the grafts (21). 
MDSC- dependent expansion of Treg that promote of cardiac allograft survival in mice (22) as well as in 
kidney transplant patients (23) has also been reported. 
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Type 1 autoimmune diabetes 
The role for MDSC in type 1 autoimmune diabetes (T1D) has been recently studied. Mouse 
studies demonstrated increased number of MDSC associated with B cell depletion treatment aimed to 
improve T1D. Further evidence is provided from a mouse model of T1D where non-diabetic NOD/SCID 
mice were injected with inflammatory T cells from diabetic NOD mice. Adoptive transfer of MDSC from 
mice with allogeneic tumor cells was found to delay the onset of hyperglycemia (21, 24). A recent study 
compared the number of CD11b
high
 Gr-1
int
 MDSC in the peripheral blood, spleen as well as in the 
pancreatic islets of prediabetic and newly diabetic NOD mice. The authors established that the onset of 
diabetes was associated with an expansion of MDSC in the peripheral blood while the number of MDSC 
in the islets significantly decreased. These changes were absent in prediabetic mice (25).  
In humans, the frequency of MDSC in peripheral blood mononuclear cells (PBMC) of T1D 
patients using surface markers CD11b
+
 CD33
+
 within HLA-DR
low/neg 
cells is increased. While healthy 
control subjects had a very low frequency, the number of MDSC was significantly increased in the 
peripheral blood of T1D patients. The cells were also characterized functionally, and were shown to 
suppress T cell proliferation (25).  
Rheumatoid arthritis  
 Rheumatoid arthritis (RA) is progressive inflammatory autoimmune disease leading to the 
destruction of articular cartilage and bone. CD4+ T cells, especially interleukin (IL)-17 producing T helper 
Th17 cells, are important in chronic inflammatory diseases. Th17 have been suggested as major effector 
cells participating in the pathogenesis of RA but the underlying mechanisms are not clearly known. 
Recent studies investigated the possible role of MDSC as well as the correlation with TH17 cells in both 
murine models of experimental autoimmune arthritis and in RA patients. MDSC with granulocytic 
phenotype were detected in the synovial fluid (SF) of mice with proteoglycan-induced arthritis (26). In a 
collagen-induced mouse model of RA, granulocytic MDSC were isolated from the spleens of arthritic 
mice. These cells had suppressive functions in vitro, and decreased the severity of joint inflammation 
upon adoptive transfer (27). Contrary to previous studies suggesting a protective role of MDSC in RA, a 
recent study has shown that expansion of MDSC corresponds with progression in mice with 
autoimmune arthritis. The authors also determined a positive correlation between MDSC numbers and 
Th17 cells in the spleen and affected joints. MDSC from arthritic mice did display a contact-dependent T 
cell suppressive capacity ex vivo, but were highly efficient in stimulating the differentiation of Th17 
producing cells. Elimination of MDSC in these mice actually reduced disease severity and resulted in 
decrease levels of Th17 cells, and these effects could be reversed by adoptive transfer of m-MDSC (28). 
Increased numbers of circulating MDSC were detected in the PMBC of RA patients when 
compared with healthy controls (HC). This study also investigated the number of Th17 cells as well as 
plasma levels of pro-inflammatory cytokines and Arg-1. The frequency of Th17 cells in RA patients was 
significantly higher than in HC but correlated negatively with the frequency of MDSC and plasma Arg-1. 
MDSC frequency and plasma TNF-α levels were negatively correlated (29).  
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A recent paper describing the presence of granulocytic MDSC-like cells in the SF of RA patients 
indicated that these cells are capable of suppressing the proliferation of autologous T cells in a non-
specific manner (anti-CD3/CD28 Ab-induced) and in an allo-Ag-induced manner (30). In RA patients with 
high disease activity, elevated MDSC numbers were found compared with HC or patients with low 
disease activity. Furthermore, there was a positive correlation between MDSC infiltration and IL-17 
levels in synovial fluid of patients. However, the frequency of MDSC in the peripheral blood was 
negatively correlated with the number of Th17 cells (28). 
 
Systemic lupus erythematosus 
Systemic lupus erythematosus (SLE) is considered a prototypical systemic autoimmune disorder. 
Elevated levels of antinuclear antibodies (ANAs) and cellular infiltration of various organs, including the 
skin, heart, and kidney are the hallmarks of the condition which predominantly affects women. The 
dysfunction of many components of the immune regulatory network, mainly T cells, is central to the 
development of the disease. Lately, the possible involvement of MDSC in SLE associated organ injury has 
also been addressed. Using the lupus-prone MRL-Fas 
lpr 
mice, a study identified increased frequency of 
CD11b
+
 Gr-1
low
 cells during disease progression in both the affected kidney and peripheral blood. The 
cells were found to suppress CD4
+
 T-cell proliferation in vivo through arginase-1 (31).  
A recent article found cellular and functional differences in myeloid cells between male and 
female lupus-prone (NZB × NZW) F1 mice. Adjacent to the spleen’s B cell follicles, a set of Gr-1
high
Ly-
6G+CD11b+ myeloid cells increased in male (NZB × NZW) F1 mice compared with female mice. These 
cells directly inhibited cytokine-induced differentiation of naive B cells into antibody-secreting cells. 
Additionally, the administration of depleting anti-Gr-1 mAb resulted in increased production of 
antinuclear autoantibodies in male mice only. The authors offer a hypothesis of a male-driven inhibitory 
mechanism to control B cell pathogenesis, which delays/prevents the development of the disease in 
otherwise genetically predisposed male (NZB × NZW) F1 mice (32). 
Another study using the similar model, evaluated the extracellular trap (ET) formation and the 
production of ROS. Both impaired expansion and functional defects of g-MDSC in the lymphoid organs of 
mice with established disease were observed. Increased elimination of g-MDSCs due to ET formation 
was mediated by cytokines from the proinflammatory microenvironment. Inhibition of ROS generation 
reduced ET release. The data suggest a likely contribution of g-MDSC to the mechanisms of the disease 
(33). 
In humans, female patients with SLE showed a higher frequency of MDSC in PBMC and a higher 
level of tumor necrosis factor α (TNF-α) in serum compared with male patients. Additionally, estradiol 
level in the serum of female patients showed a positive correlation with the frequency of MDSC. The 
study also investigated the role of 17β-estradiol in mice; and found that 17β-estradiol may contribute to 
the accumulation of MDSC in blood by promoting TNF-α secretion, which increases the frequency of 
CD11b+Gr-1+ (34).  
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Further support for a pathogenic role for MDSC in human SLE is suggested by a recent study. In 
the peripheral blood of patients with active SLE, a significant increase in the number of both CD14(+) 
CD66b(-) monocytic and CD14(-) CD66b(+) granulocytic MDSC was detected. The increase in numbers 
was positively correlated with serum Arg-1 activity, Th17 responses as well as disease severity. The 
authors also demonstrated, in a humanized SLE model, that MDSC induced renal injury via Th17 
response in an Arg-1-dependent manner (35).  
Inflammatory Bowel Disease  
There are several studies suggesting a role for MDSC in experimental inflammatory bowel 
disease (IBD). In an IBD transgenic mouse model of enterocyte-specific expression of hemagglutinin 
(HA), repeated transfer of HA-specific CD8+ T cells resulted in expansion of MDSC. Isolated MDSC 
(CD11b+Gr-1+ cells) were protective and suppressed development of disease after the first transfer of 
CD8+ cells (36). Similarly, in a model of dextrane-suphate sodium (DSS) induced colitis, adoptive transfer 
of splenic CD11b+Gr-1+ cells into DSS-treated mice proved to be beneficial (37). In mice with colitis 
induced by 2, 4, 6-trinitrobenzenesulfonic acid (TNBS) MDSC are detected in the spleen and colonic 
lamina. Adoptive transfer of MDSC from colitis mice into animals challenged with TNBS decreased 
intestinal inflammation, levels of IFN-γ, IL-17, and TNF, as well as percentage of spleen MDSC when 
compared with controls (38). Another study described that during chronic colitis; adoptively transferred 
Ly6C
high
 monocytes are recruited into the colon and differentiate into inflammatory cells (39).  
Hyperactivation of  Signal Transducer and Activator of Transcription (STAT)3, a known regulator 
of MDSC expansion, has been associated recently with protection from experimental colitis. Acute and 
chronic colitis was induced in gp130(757F/F) mice as well as in mice with myeloid-specific STAT3-
deficiency (LysMcre/STAT3(flox); gp130(757F/F) LysMcre/STAT3(flox). Cells obtained from spleen, 
mesenteric lymph node and colon were analyzed for different myeloid cell populations, and the function 
of MDSC and LPS-stimulated peritoneal macrophages were analyzed in vitro and in vivo. The resistance 
to colitis in gp130 (757F/F) mice was associated to myeloid-cell specific STAT3 activation, MDSC 
expansion and increased production of cytokines with suppressive and protective effects (40). 
MDSC or MDSC-like cells have been also detected in IBD patients. Significantly higher levels of 
CD14+HLA-DR-/low cells were found in the peripheral blood in patients with IBD compared with healthy 
subjects. Frequency of MDSC appeared to correspond with disease activity (41).  
 
Experimental autoimmune encephalomyelitis  
Experimental autoimmune encephalomyelitis (EAE) is a widely used animal model for multiple 
sclerosis (MS), and different studies have investigated the role of MDSC in EAE. Circulating Ly6C
+
 myeloid 
precursors were shown to migrate to the CNS and maintain disease progression (42, 43), while other 
studies have demonstrated a possible regulatory role of Ly6C
+
 myeloid precursors in the same model 
(44, 45). A detailed study described accumulation of CD11b
high
 Ly6G
+
Ly6C
−
 g-MDSC in the spleen of mice 
with EAE, prior to resolution of inflammation. Additionally, the authors found that in vivo transfer of g-
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MDSC, purified from an autoimmune environment generated by the injection of a self-Ag plus adjuvant, 
reduced the expansion of autoreactive T cells and inhibited pathogenic Th1 and Th17 immune responses 
in a programmed death ligand (PD-L1)/IFN-γ–dependent pathway. Increased accumulation of g-MDSCs 
at the meningeal lesions of spinal cord was also observed, suggesting that, in addition to the peripheral 
lymphoid organs, the cells act at the target tissue as well (46). Other studies also demonstrated that the 
development of EAE in mice is accompanied with an expansion of CD11b
+ 
Gr-1
+
 cells, which inhibit T cell 
functions in vitro. MDSC enhanced the differentiation of naive CD4
+
 T cell precursors into Th17 cells. 
Selective depletion of MDSC resulted in reduced severity of EAE correlated with reduced Th17 cells and 
inflammatory cytokines (IL-17A and IL-1β) in the lymphoid tissues and spinal cord, and adoptive transfer 
of MDSC restored disease progression (47). 
MDSC are significantly increased in the peripheral blood of patients with active MS compared 
with patients in remission or healthy controls. Several patients were monitored over time, and a 
decrease in circulating MDSC numbers was associated with remission. Similarly to the mouse model, 
morphological analysis revealed a granulocytic phenotype. The sorted cells suppressed the activation 
and proliferation of autologous T cells in vitro (46).  
 
Autoimmune hepatitis 
Experimental hepatitis is a well-established animal model to study T-cell mediated hepatic injury 
resembling clinical conditions. MDSC accumulate in the liver during Concanavalin A (Con-A), as well as D-
galactosamine (D-gal) and picryl chloride-induced hepatitis, and protect the liver from excessive damage 
(48, 49). Different studies identified that different subsets of MDSC may accumulate in the liver in these 
models, and the subsets use different suppressive mechanisms. Cannabidiol or IL-25 leads to increased 
numbers of hepatic CD11b
+
 Gr-1
+
 cells, and alters the ratio of g-MDSC to m-MDSC. T cell responses are 
inhibited in an arginase-dependent manner, dominantly by m-MDSC (48, 50). Treatment with 
sphingosine-1-phosphate receptor agonist FTY720 also recruits MDSC to the liver, but the suppressive 
function depends on iNOS and NO production (51). Another study in Con-A-mediated hepatitis 
described that, although the number of both MDSC subtypes increased; only m-MDSC were able to 
suppress T cell responses and decrease the extent of liver damage. Similar observation was made in 
TGFβ1
-/-
 mice with acute liver damage, where the number of both subtypes expanded in the liver with 
only m-MDSC suppressing T cells via iNOS (52).  
In humans, data are limited. Early reports described increased numbers of CD11b
+
 cells in 
biopsies obtained from patients with active autoimmune hepatitis (53). A different study identified, in 
the peripheral blood, “highly activated” monocytes accompanying liver-antigen-specific T cells secreting 
IFN-γ (54).  
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Conclusions 
The variety of activities and effects associated with MDSC in autoimmune models and diseases 
(summarized in Table 2) makes it difficult to offer a comprehensive hypothesis explaining the role of 
these cells in autoimmunity. MDSC display extraordinary heterogeneity and plasticity, have multiple 
phenotypes and may inhibit T cell responses by multiple mechanisms. Their differentiation, expansion 
and migration also are regulated by numerous factors. Complete characterization of these cells is not 
always possible, or simply lacking in some studies. 
Because of the exceptional diversity, sometimes incomplete or inherently limited nature of data 
such as in human studies, comparison among reports is challenging. The difficulties of these studies and 
the apparent need of harmonizing MDSC phenotyping are underlined by findings of a new report. 
Comparing  immunophenotyping profiles of the same sets of MDSC performed in over 20 laboratories 
disclosed high inter-laboratory variance for all MDSC subsets. The main cause associated with variance 
was heterogeneous gating strategy. A detailed analysis, using harmonized marker combinations and 
gating parameters is important in different clinical settings, and would greatly facilitate evaluating 
results of different studies (55). In addition to identifying phenotypical and functional characteristics, the 
interactions of MDSC with other cell types also need to be explored. 
Despite the contradictions, it is apparent that mouse CD11b
+
Gr-1
+
 cells isolated from target site/ 
inflammatory environment are capable of inhibiting T cells in vitro, using different mechanisms including 
production of NO, induction of T cell apoptosis and arginase-1. Endogenous MDSC in vivo, however, 
were found in several systems ineffective at alleviating the signs and symptoms of autoimmune 
diseases. CD11b
+
Gr-1
+
 cells may be pro-inflammatory, and possibly can even aggravate the disease as 
reported in EAE. Exogenously expanded MDSC on the other hand can clearly improve tissue damage as 
suggested by results in mouse models of IBD or T1D.  
These contrasting findings between the activities of endogenous and exogenous MDSC have not 
yet been resolved. It is possible that the differentiation and activation of these cells locally is inhibited or 
incomplete due to certain components from the inflammatory microenvironment, resulting in the 
absence of suppressive function. Intrinsic dysfunction of MDSC in vivo may also be a contributing factor 
to autoimmune tissue damage. MDSC expand and accumulate in response to local inflammation, but as 
the dysfunctional cells are unable to inhibit the T cell response, further broadening of the inflammatory 
process and additional recruitment of MDSC may ensue. Isolating the MDSC from the inflammatory site 
probably restores function by eliminating the inhibitory environment, and the now ”exogenous” cells 
are suppressive both in vitro and upon adoptive transfer. 
The obvious ability of exogenously applied MDSC to inhibit autoimmune tissue damage in 
murine models may offer a promising opportunity for the treatment of human autoimmune diseases. As 
several methods have been developed to expand MDSC in vitro from different cellular sources 
(peripheral blood, bone marrow and embryonic/hematopoietic stem cells), large scale production of 
MDSC seems feasible (56-58). Nonetheless, certain risks associated with such treatment remain to be 
considered. These in vitro expanded cells would not be specific for T cells recognizing autoantigens, and 
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may also inhibit protective immune responses. Administration of MDSC may result in release of 
inflammatory mediators. Additionally, it would also be difficult to control the migration and 
accumulation of the injected cells. The full utilization of MDSC as cellular therapy in human autoimmune 
diseases remains hindered by these concerns and by our still incomplete understanding of their 
phenotype, differentiation, functions, and interactions with the inflammatory microenvironment. 
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Table 1. Major phenotypic markers of MDSC 
Marker Mouse M-MDSC Mouse G-MDSC Human M-MDSC Human G-MDSC 
CD11b + + + + 
CD14 n/a n/a + low 
CD15 n/a n/a - + 
CD39 n/a n/a + + 
CD66b n/a n/a - + 
GR-1 low bright n/a n/a 
HLA-DR n/a n/a low/- - 
Lin n/a n/a - - 
Ly-6G - + n/a n/a 
Ly-6C + low n/a n/a 
        n/a: not applicable 
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Table 2.  MDSC in autoimmune syndromes 
Disease Species Cell 
type/Phenotype 
Origin of 
cells 
Effect Reference 
T1D Mouse CD11b
high
 Gr-1
int
 peripheral 
blood 
proinflammatory 25 
Human CD11b
+
 CD33
+
 HLA-
DR
low/neg
 
peripheral 
blood 
proinflammatory 25 
RA Mouse G-MDSC spleen suppressor 27 
Mouse MDSC joint tissue proinflammatory 28 
Human MDSC synovial fluid proinflammatory 28 
Human MDSC peripheral 
blood 
suppressor 29 
Human G-MDSC synovial fluid suppressor 30 
SLE Mouse G-MDSC spleen suppressor (in 
males) 
32 
Mouse G-MDSC lymphoid 
organs 
proinflammatory 33 
Human G-MDSC peripheral 
blood 
proinflammatory 34 
Human M- and G-MDSC peripheral 
blood 
proinflammatory 35 
IBD Mouse G-MDSC adoptive 
transfer 
suppressor 36, 37 
Mouse G-MDSC adoptive 
transfer 
suppressor 38 
Mouse M-MDSC adoptive 
transfer 
proinflammatory 39 
Mouse STAT3+ MDSC spleen, lymph 
node 
suppressor 40 
Human CD14+HLA-DR-/low peripheral 
blood 
suppressor 41 
EAE Mouse M-MDSC CNN proinflammatory 44, 45 
Mouse G-MDSC adoptive 
transfer 
suppressor 46 
Mouse G-MDSC adoptive 
transfer 
proinflammatory 47 
Human G-MDSC peripheral 
blood 
suppressor 46 
AIH 
 
Mouse G-MDSC liver suppressor 50, 51 
Mouse M- and G-MDSC liver suppressor (M) 52 
T1D - type 1 autoimmune diabetes ;  RA - rheumatoid arthritis; SLE - systemic lupus 
erythematosus; IBD - inflammatory bowel disease ; EAE - experimental autoimmune 
encephalomyelitis ; AIH - autoimmune hepatitis 
 
